[go: up one dir, main page]

AU2002365622A1 - Novel glucagon antagonists - Google Patents

Novel glucagon antagonists

Info

Publication number
AU2002365622A1
AU2002365622A1 AU2002365622A AU2002365622A AU2002365622A1 AU 2002365622 A1 AU2002365622 A1 AU 2002365622A1 AU 2002365622 A AU2002365622 A AU 2002365622A AU 2002365622 A AU2002365622 A AU 2002365622A AU 2002365622 A1 AU2002365622 A1 AU 2002365622A1
Authority
AU
Australia
Prior art keywords
glucagon antagonists
novel glucagon
novel
antagonists
glucagon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002365622A
Inventor
Inge Thoger Christensen
Anker Steen Jorgensen
Janos Tibor Kodra
Jesper Lau
Peter Madsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2002365622A1 publication Critical patent/AU2002365622A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2002365622A 2001-12-03 2002-11-28 Novel glucagon antagonists Abandoned AU2002365622A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200101789 2001-12-03
DKPA200101789 2001-12-03
DKPA200201117 2002-07-18
DKPA200201117 2002-07-18
PCT/DK2002/000800 WO2003048109A1 (en) 2001-12-03 2002-11-28 Novel glucagon antagonists

Publications (1)

Publication Number Publication Date
AU2002365622A1 true AU2002365622A1 (en) 2003-06-17

Family

ID=26069105

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002365622A Abandoned AU2002365622A1 (en) 2001-12-03 2002-11-28 Novel glucagon antagonists

Country Status (4)

Country Link
EP (1) EP1463715A1 (en)
JP (1) JP2005511683A (en)
AU (1) AU2002365622A1 (en)
WO (1) WO2003048109A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572922B2 (en) 2003-01-27 2009-08-11 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
EP1758859B1 (en) * 2004-05-28 2013-07-17 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
SI1758853T1 (en) * 2004-06-14 2010-05-31 Lilly Co Eli Glucagon receptor antagonists, preparation and therapeutic uses
US7622491B2 (en) * 2004-08-13 2009-11-24 Metabolex Inc. Modulators of PPAR and methods of their preparation
PT1856090E (en) * 2005-02-11 2009-11-18 Lilly Co Eli Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
EP1863755A1 (en) 2005-03-21 2007-12-12 Merck & Co., Inc. Substituted aryl and heteroaryl derivatives
JP2008534593A (en) 2005-03-30 2008-08-28 メルク エンド カムパニー インコーポレーテッド Glucagon receptor antagonist compounds, compositions containing such compounds, and methods of use thereof
US20090239944A1 (en) * 2005-06-24 2009-09-24 D Orazio Daniel Novel Use of Organic Compounds
CN101300232A (en) 2005-07-26 2008-11-05 默克公司 Process for the synthesis of substituted pyrazoles
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
BRPI0618349A2 (en) 2005-11-17 2011-08-23 Lilly Co Eli pharmaceutically acceptable compound or salt thereof, pharmaceutical composition, and use of a compound or salt thereof
CN101312940B (en) 2005-11-17 2012-11-14 伊莱利利公司 Glucagon receptor antagonists, preparation and therapeutic uses
DK1951659T3 (en) 2005-11-18 2010-10-11 Lilly Co Eli Glucagon Receptor Antagonists, Preparation and Therapeutic Use thereof
WO2007120270A2 (en) 2005-11-22 2007-10-25 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
BRPI0618745A2 (en) * 2005-11-23 2011-09-13 Lilly Co Eli compound or a salt thereof, pharmaceutical composition, and use of a compound or a salt thereof
WO2007111864A2 (en) 2006-03-23 2007-10-04 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2009537525A (en) 2006-05-16 2009-10-29 メルク エンド カムパニー インコーポレーテッド Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
KR20170085615A (en) 2007-02-09 2017-07-24 메타베이시스 테라퓨틱스, 인크. Novel antagonists of the glucagon receptor
EP2210876B1 (en) * 2007-11-01 2015-05-20 Takeda Pharmaceutical Company Limited Heterocyclic compound as glucagon antagonist
CN102015641B (en) * 2008-03-05 2014-01-01 武田药品工业株式会社 Heterocyclic compound
US8623818B2 (en) 2008-05-16 2014-01-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonists, compositions, and methods for their use
CA2966273C (en) 2008-08-13 2019-08-27 Metabasis Therapeutics, Inc. Glucagon antagonists
CN101768149B (en) * 2008-12-30 2013-10-30 成都地奥制药集团有限公司 Beta- aminoketone (alkamine) derivatives and use thereof
WO2010088061A1 (en) 2009-01-28 2010-08-05 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
PE20100443A1 (en) * 2009-02-06 2010-06-25 Takeda Pharmaceutical DERIVATIVES OF PHENYL-CARBONYL-AMINO-PROPANOIC ACID AS ANTAGONISTS OF GLUCAGON
WO2011027849A1 (en) * 2009-09-04 2011-03-10 武田薬品工業株式会社 Heterocyclic compound
CA2822017C (en) 2010-12-23 2015-04-07 Pfizer Inc. Glucagon receptor modulators
CN103370306B (en) 2011-02-08 2015-12-02 辉瑞大药厂 Glucagon Receptor Modulators
WO2012162409A1 (en) * 2011-05-23 2012-11-29 Janssen Pharmaceutica Nv Biphenyl derivatives useful as glucagon receptor antagonists
AU2012258771A1 (en) * 2011-05-23 2013-11-14 Janssen Pharmaceutica Nv Picolinamido - propanoic acid derivatives useful as glucagon receptor antagonists
WO2013014569A1 (en) 2011-07-22 2013-01-31 Pfizer Inc. Quinolinyl glucagon receptor modulators
WO2013138753A1 (en) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
BR112015020391B1 (en) 2013-02-22 2022-07-26 Samumed, Llc GAMMA-DICETONES AS WNT/BETA-CATENIN SIGNALING PATHWAY ACTIVATORS
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US10076504B2 (en) 2014-06-12 2018-09-18 Ligand Pharmaceuticals, Inc. Glucagon antagonists
CN107205970A (en) 2014-11-05 2017-09-26 弗莱塞斯生物科学公司 Immunomodulator
WO2017215586A1 (en) * 2016-06-14 2017-12-21 浙江海正药业股份有限公司 Amide derivatives, preparation process thereof and use thereof in medicine
AU2018212616A1 (en) * 2017-01-27 2019-08-29 Genfit RORgamma modulators and uses thereof
JP2021513564A (en) 2018-02-13 2021-05-27 リガンド・ファーマシューティカルズ・インコーポレイテッド Glucagon receptor antagonist
CN110357813A (en) * 2018-04-09 2019-10-22 信达生物制药(苏州)有限公司 A kind of new indole amine 2,3- dioxygenase inhibitor and its preparation method and application

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU2001265834A1 (en) * 2000-06-23 2002-01-08 Novo Nordisk A/S Glucagon antagonists/inverse agonists

Also Published As

Publication number Publication date
JP2005511683A (en) 2005-04-28
EP1463715A1 (en) 2004-10-06
WO2003048109A1 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
AU2002365622A1 (en) Novel glucagon antagonists
AU2001255798A1 (en) Glucagon antagonists
AU2002341834A1 (en) Antagonists
AU2002360508A1 (en) Substituted hydroxyethylamines
SI1671949T1 (en) Substituted Pyridinylamines
AU2002367404A1 (en) Redox-switchable materials
AU2002367336A1 (en) Stairway
AU2003291959A1 (en) Novel glucagon antagonists
AU2002359320A1 (en) Novel anit-infectives
AU2002365655A1 (en) 5-ht7 receptor antagonists
AU2002251024A1 (en) Substituted fluoroalcoxyphenylsulfonylurea
PL362643A1 (en) Substituted fluoroalcoxyphenylsulfonylurea
AU2002321215A1 (en) Substituted 4-aminocyclohexanols
PL368050A1 (en) Substituted 4-aminocyclohexanols
AU2002241899A1 (en) Tip39 polypeptides
AU2002247861A1 (en) Modified calcitonin
AU2002346030A1 (en) Novel receptors
WO2002077001A9 (en) Novel receptors
PL364601A1 (en) Substituted benzo-nitro-heterocycles
AUPR918701A0 (en) Tile
AU2002346278A1 (en) Tile
AU2002360933A1 (en) Antagonists for alpha4-integrins
AU2002311774A1 (en) Novel receptors
AU2002310084A1 (en) Ccr4 antagonists
AU2002363642A1 (en) Nk1 antagonists

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase